Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy.
Jabr
Fadi I
FI
Ordinario
Maria Margarita D
MM
D000998:Antiviral Agents / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012965:Sodium Chloride / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D001786:Blood Glucose; D007328:Insulin; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012965:Sodium Chloride; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a